Survival analysis of patients with tricuspid regurgitation grouped according to comorbidities and echocardiographic variables. For many years, the tricuspid was classified as the “forgotten valve,” due to the scarce possibility of treatment beyond symptom control in patients with heart failure. However, in recent years, there has been an improvement in the treatment of the valve<a href="https://solaci.org/en/2023/03/28/survival-in-patients-with-tricuspid-regurgitation-according-to-clinical-and-echocardiographic-variables-clusters/" title="Read more" >...</a>
TriClip: Tricuspid Regurgitation Dedicated Device
Severe tricuspid regurgitation (TR) is difficult to manage and is associated to high morbimortality. Surgical repair is complex and not free from complications: its mortality rate ranges from 5 to 20% and depends on series, surgeon and center expertise. Edge-to-edge repair with clips has become a valid alternative to treat this disease, but most data<a href="https://solaci.org/en/2023/03/22/triclip-tricuspid-regurgitation-dedicated-device/" title="Read more" >...</a>
ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation
Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is complex, and mortality is not low. Dr. Paul Sorajja presented the results of the Pivotal Triluminate study to demonstrate the safety and efficacy of edge-to-edge treatment (transcatheter edge-to-edge repair, TEER) in tricuspid regurgitation. Three hundred and fifty patients<a href="https://solaci.org/en/2023/03/08/acc-2023-triluminate-pivotal-edge-to-edge-treatment-in-patients-with-tricuspid-regurgitation/" title="Read more" >...</a>
Watch Again Tricuspid Valve: New Options for Structural Percutaneous Treatment
Enjoy once again a new SOLACI Sessions event: “Tricuspid Valve: New Options for Structural Percutaneous Treatment” on our YouTube channel. The event, sponsored by P&F, was attended by renowned opinion leaders in the region and featured important dissertations and case study discussions. Watch it here below! Tricuspid Valve: New Options for Structural Percutaneous Treatment
Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair
Tricuspid failure (TF) mostly affects the elderly and, because of this, is associated with comorbidities that increase surgical risk. Tricuspid edge to edge repair (TEER) has surged as a valid alternative for the mitral valve in high-risk patients and, at present, is increasingly being used for tricuspids. One of the complications following TEER is acute<a href="https://solaci.org/en/2022/10/12/prognostic-impact-of-acute-kidney-injury-following-tricuspid-transcatheter-edge-to-edge-repair/" title="Read more" >...</a>
SOLACI-SOCIME 2022 | Tricuspid Edge-to-edge repair. When the Triclip is indicated?
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Luis Marroquín, entitled “Tricuspid Edge-to-edge repair. When the Triclip is indicated?”
Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL
About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>
TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months
Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade. Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness. The bicaval<a href="https://solaci.org/en/2022/07/15/tricvalve-in-patients-with-severe-tricuspid-regurgitation-promising-results-at-6-months/" title="Read more" >...</a>
EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation
At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results. The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>
EuroPCR 2022 | Real World Outcomes on Edge-to-Edge Tricuspid Valve Repair: 30 Day Outcomes of the TriClip bRight
This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk. It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior<a href="https://solaci.org/en/2022/05/26/europcr-2022-real-world-outcomes-on-edge-to-edge-tricuspid-valve-repair-30-day-outcomes-of-the-triclip-bright/" title="Read more" >...</a>